METABOLIC AND CYTOKINE THERAPIES IN SEPSIS
Eichacker PQ, Natanson C.
Increasing evidence that the risks of rhAPC may outweigh its benefits.
ICM 2007,33,396-399 Eichacker
After disappointing results from ADDRESS, ENHANCE and RESOLVE, is the tide turning against APC……..?
Finfer S, Ranieri VM, Thompson BT, Barie PS, Dhainaut JF et al.
Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.
ICM 2008,34,1935-1947 Finfer
Once again, that nice sweet Dr Finfer will make it all safe, with PROWESS-SHOCK….
Kreymann KG, de Heer G, Nierhaus A, Kluge S.
Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock
CCM 2007,35,2677-2685 Kreymann
A new study, two conflictingmeta-analyses, and twoeditorials, all in one issue of CCM – new hot topic?
The NICE-SUGAR Study Investigators
Intensive versus conventional glucose control in intensive care patients
NEJM 2009,360,1283-1297 NICE-SUGAR
The end of tight glucose control as we know it? Read the editorial as well.
Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M et al.: German Competence Network Sepsis (SepNet).
Intensive insulin therapy and pentastarch resuscitation in severe sepsis.
NEJM 2008,358,125-139 Brunkhorst
The VISEP trial: two completely unrelated studies combined into one! Here’s a damning indictment.
Sprung CL, Annane D, Keh D, Moreno R, Singer M et al.: CORTICUS Study Group.
Hydrocortisone therapy for patients with septic shock.
New England Journal of Medicine 2008; 358: 111-24. NEJM Full Text
So what was the difference between CORTICUS and Annane’s (previous) study?
Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM et al.
Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008.
ICM 2008,34,17-60 Dellinger
Critical Care Medicine 2008; 36: 296-327. PubMed Abstract (CCM)
Less aPC, less steroids, WAY more text than 2004…..